A potential drug to treat corona’s patients … and a “single condition” to speed up its production


The French CEO of Sanofi Pharmaceuticals, Paul Hudson, said on Thursday that the company will be able to produce millions of doses of hydroxychloroquine for patients of the emerging coronavirus if the old malaria drug is proven effective in clinical trials.

Hudson, who took over as CEO in September, said in an interview that the company was conducting manufacturing operations with 93 percent capacity during the pandemic.

He added that Sanofi decided to increase the production of her medications to ensure the maintenance of supplies for hospitals in Europe and the United States at a time when she faces unprecedented pressure from patients, who suffer from respiratory complications due to the outbreak, which risks putting health systems overloaded.

But he indicated that the company was not operating at full production capacity because the workers, who had symptoms of the disease and those who had mixed with it, had been sent to their homes for two weeks, according to Reuters.

The company began producing all possible quantities of hydroxychloroquine in February, after Chinese data indicated that a drug intended to treat malaria could help some Covid-19 patients.

Sanofi sells the drug, which has been in use since the 1950s, with a brand name “Blackwinell” in some countries.

Sanofi is also working on developing two possible vaccines for the disease and is testing the drug “Kevzara” used to treat rheumatism as a potential drug for Covid-19, a drug it manufactures with Reginero.

The European Commission has stated that there is no evidence yet that hydroxychloroquine is effective in healing Corona patients.

            //}, 3000);
    //$(window).bind('scroll ');
    $ (window) .scroll (function () {
        if (alreadyLoaded_facebookConnect == false) {
            alreadyLoaded_facebookConnect = true;
            // $ (window) .unbind ('scroll');
            // console.log ("scroll loaded");

            (function (d, s, id) {
                var js, fjs = d.getElementsByTagName (s)[0];
                if (d.getElementById (id)) return;
                js = d.createElement (s); js.id = id;
                js.async = true;
                js._https = true;
                js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322";
                fjs.parentNode.insertBefore (js, fjs);
            } (document, 'script', 'facebook-jssdk'));
            // pre_loader ();
            // $ (window) .unbind ('mousemove');
            // setTimeout (function () {
            // $ ('# boxTwitter'). html ("");
            //}, 3000);

            var scriptTag = document.createElement ("script");
            scriptTag.type = "text / javascript"
            scriptTag.src = "https://news.google.com/scripts/social.js";
            scriptTag.async = true;
            document.getElementsByTagName ("head")[0].appendChild (scriptTag);

            (function () {
                $ .getScript ("https://news.google.com/scripts/social.js", function () {});


//$(window).load(function () {
// setTimeout (function () {
// // add the returned content to a newly created script tag
// var se = document.createElement ('script');
// se.type = "text / javascript";
// //se.async = true;
// se.text = "setTimeout (function () {pre_loader ();}, 5000);";
// document.getElementsByTagName ('body')[0].appendChild (se);
//}, 5000);


Please enter your comment!
Please enter your name here